Drug Manufacturers - Specialty & Generic News

AFT Pharmaceuticals reports ongoing sales growth and R&D progress

AFT Pharmaceuticals has achieved sustained growth at the start of the 2027 FY and is on track to reach its $300 million revenue target.

Colin Sandell-Hay

07 Jul 2026 09:36 (AEST)

ASX News Healthcare Steel Drug Manufacturers - Specialty & Generic Basic Materials

Syntara (ASX:SNT) has reported encouraging interim results from its Phase 2 study of SNT-4728, providing the first clinical evidence that the company’s novel anti-inflammatory therapy may be targeting a key biological process linked to the development of Parkinson’...

Isaac McIntyre

06 Jul 2026 12:34 (AEST)

ASX News Healthcare Drug Manufacturers - Specialty & Generic

Syntara has reported statistically significant reductions in brain inflammation in an early-stage Parkinson's disease study.

Seja Al Zaidi

06 Jul 2026 11:54 (AEST)

ASX News Healthcare Drug Manufacturers - Specialty & Generic

AFT Pharmaceuticals has obtained positive FDA) approval to proceed with the next stage of its injectable iron research and development.

Colin Sandell-Hay

24 Jun 2026 09:08 (AEST)

ASX News Healthcare Drug Manufacturers - Specialty & Generic

Percheron Therapeutics has achieved a major milestone in the commercial development of its lead candidate HMBD-002.

Colin Sandell-Hay

17 Jun 2026 11:36 (AEST)

ASX News Healthcare Drug Manufacturers - Specialty & Generic

As Syntara advances a diversified pipeline, it's now approaching what could be one of the company's most important near-term catalysts.

TML Editorial

03 Jun 2026 09:43 (AEST)

ASX News Healthcare Drug Manufacturers - Specialty & Generic

Syntara (ASX:SNT) has recently completed an $8m Placement of new shares to new and existing investors, and in conjunction, announced a Share Purchase Plan (SPP) to raise a further $2m from existing eligible shareholders.Listen to the HotCopper podcast for in-depth discussions and insights on all ...

Isaac McIntyre

22 May 2026 10:06 (AEST)

ASX News Contributors & Collaborations Healthcare Drug Manufacturers - Specialty & Generic

AFT Pharma founder and chief executive Hartley Atkinson talks strong sales growth, ongoing R&D initiatives, and a boost in licensing income.

Isaac McIntyre

21 May 2026 09:34 (AEST)

ASX News The Watchlist Healthcare Drug Manufacturers - Specialty & Generic

Syntara has had a positive outcome from its in person Type C meeting with the US FDA for a Phase 2b trial design.

TML Editorial

01 May 2026 15:10 (AEST)

ASX News Healthcare Drug Manufacturers - Specialty & Generic

Syntara has received positive feedback from the US FDA for the phase 2b study design for its amsulostat candidate.

Colin Sandell-Hay

28 Apr 2026 13:20 (AEST)

ASX News Healthcare Drug Manufacturers - Specialty & Generic

AFT Pharmaceuticals (ASX:AFP) is in a red-hot position as we head straight into FY26’s fourth quarter in Australia, and founder and managing director Hartley Atkinson believes it’s only going to get better as the growing Oz-based multinational pharmaceutical compan...

Isaac McIntyre

07 Apr 2026 09:15 (AEST)

ASX News The Watchlist Healthcare Drug Manufacturers - Specialty & Generic

In the face of a new war crisis weighing heavily on both equities and economics alike, value hunters (both long- and short-term minded alike) are chasing down new targets for 2026. Listen to the HotCopper podcast for in-depth discussions and insights on all the biggest headlines from throughout t...

Jonathon Davidson

19 Mar 2026 16:24 (AEDT)

ASX News Healthcare Drug Manufacturers - Specialty & Generic

Syntara has today added ~$2 million to its coffers – $1.7M to be exact – after receiving a milestone payment from Parkinson's U.K.

Jonathon Davidson

19 Mar 2026 14:44 (AEDT)

ASX News Healthcare Drug Manufacturers - Specialty & Generic

Drug Manufacturers - Specialty & Generic News

AFT Pharmaceuticals reports ongoing sales growth and R&D progress

Syntara shows encouraging first signals it can impact the path to Parkinson's

Syntara reports encouraging early Parkinson's trial results

FDA allows AFT’s injectable iron project clinical study to proceed

Percheron Therapeutics completes cancer treatment drug substance manufacture milestone

Can Syntara slow the path to Parkinson's? Key SNT-4728 data due this month

Specialist healthcare investors back Syntara ahead of milestone rich period

AFT Pharma delivers record FY26 as global growth accelerates

FDA greenlights Syntara’s Amsulostat Phase 2b, setting up big 2026 catalysts

Syntara receives positive feedback from FDA on amsulostat plans

US growth, injectable iron pipeline: How AFT Pharma is driving toward $300 million by FY27

Existing myleofibrosis drugs can make the condition worse. Syntara Ltd could be about to change that

Some 80% of people who develop Parkinson's present with this sleep disorder first. Syntara's treating it